Pharma-focused SK Capital reinvests in Archroma, months after rumours of potential sale

Pharma-focused private equity firm SK Capital has reinvested in portfolio company, Archroma, months after it was rumoured it could sell the business in a $1.5bn deal. SK initially acquired the business in 2013 and has since made a series of bolt-on deals for it. AltAssets reported in February this year that Apollo and Advent were poised …